Northern Trust
ZNTL icon

Northern Trust’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Northern Trust’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$277K Buy
118,186
+25,315
+27% +$65.4K ﹤0.01% 3834
2025
Q4 		$125K Sell
92,871
-1,248
-1% -$1.82K ﹤0.01% 4089
2025
Q3 		$142K Sell
94,119
-29,325
-24% -$44K ﹤0.01% 4062
2025
Q2 		$143K Sell
123,444
-338,859
-73% -$447K ﹤0.01% 4029
2025
Q1 		$735K Sell
462,303
-22,435
-5% -$48.4K ﹤0.01% 3409
2024
Q4 		$1.47M Buy
484,738
+10,513
+2% +$34.5K ﹤0.01% 3185
2024
Q3 		$1.75M Sell
474,225
-21,041
-4% -$76.5K ﹤0.01% 3084
2024
Q2 		$2.03M Sell
495,266
-28,436
-5% -$318K ﹤0.01% 2889
2024
Q1 		$8.25M Sell
523,702
-6,301
-1% -$86.7K ﹤0.01% 2168
2023
Q4 		$8.03M Sell
530,003
-10,719
-2% -$156K ﹤0.01% 2212
2023
Q3 		$10.8M Buy
540,722
+61,919
+13% +$1.57M ﹤0.01% 1946
2023
Q2 		$13.5M Buy
478,803
+51,932
+12% +$1.25M ﹤0.01% 1855
2023
Q1 		$7.34M Buy
426,871
+6,827
+2% +$138K ﹤0.01% 2224
2022
Q4 		$8.46M Buy
420,044
+3,002
+0.7% +$64.6K ﹤0.01% 2124
2022
Q3 		$9.03M Buy
417,042
+43,142
+12% +$1.18M ﹤0.01% 2048
2022
Q2 		$10.5M Buy
373,900
+34,669
+10% +$918K ﹤0.01% 1990
2022
Q1 		$15.7M Sell
339,231
-10,534
-3% -$568K ﹤0.01% 1849
2021
Q4 		$29.4M Buy
349,765
+1,433
+0.4% +$111K ﹤0.01% 1504
2021
Q3 		$23.2M Buy
348,332
+41,002
+13% +$2.37M ﹤0.01% 1688
2021
Q2 		$16.4M Buy
307,330
+24,007
+8% +$1.29M ﹤0.01% 2031
2021
Q1 		$12.3M Buy
283,323
+881
+0.3% +$37.9K ﹤0.01% 2162
2020
Q4 		$14.7M Buy
282,442
+138,550
+96% +$6.25M ﹤0.01% 2015
2020
Q3 		$4.7M Buy
143,892
+11,356
+9% +$398K ﹤0.01% 2569
2020
Q2 		$6.36M Buy
+132,536
New +$5.08M ﹤0.01% 2368

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Northern Trust's ZNTL Position: Q1 2026 in Review

Northern Trust increased its Zentalis Pharmaceuticals (ZNTL) stake by 27% in Q1 2026, buying an estimated $65.4K and bringing the position to 118,186 shares worth $277K. The position accounts for ﹤0.01% of the portfolio, ranked #3834.

Northern Trust first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $29.4M in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Northern Trust held 118,186 shares of Zentalis Pharmaceuticals worth $277K as of Q1 2026.
  • Northern Trust bought 25,315 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $65.4K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3834 holding.
  • Northern Trust first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Northern Trust's Zentalis Pharmaceuticals position peaked at $29.4M in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.